Condition
Sarcoidosis-associated small-fibre neuropathy has a specific disease context. It is not interchangeable with sports injury, back pain or general inflammation.
Evidence profile · O-011
ARA-290 / cibinetide: narrow neuropathy trials, broader claims
Real human trials can still be too narrow for the marketed claim. Small sarcoidosis-associated neuropathy studies do not establish general recovery, anti-inflammatory or pain benefits.
ARA-290, also called cibinetide, has small human trials in narrow neuropathic settings, but it is not an established general pain, recovery or anti-inflammatory treatment. Pilot studies in sarcoidosis-associated small-fibre neuropathy reported signals on symptoms and nerve measures. Their size, population and development history limit broader claims.
A clinically relevant signal should be read precisely. It applies to the studied formulation, route, patients and endpoints. It does not verify a vial sold online or justify extrapolation to healthy recovery, gut inflammation, sports injury, unrelated neuropathy or mood. Cibinetide remains without an identified UK marketing authorisation.
Trial scope
What the sarcoidosis studies tested
| Study | Population and design | Reported signal | Main limit |
|---|---|---|---|
| 2012 pilot | 22 people with sarcoidosis and small-fibre neuropathy symptoms; randomised and double blind | Improvement on a neuropathy symptom list versus placebo | Very small and exploratory; several pain measures improved similarly in both groups |
| 2013 study | Blinded placebo-controlled research in documented sarcoidosis-associated small nerve-fibre loss | Symptom and corneal nerve-fibre signals | Narrow condition, small programme and sponsor involvement |
| Later phase 2 work | Defined neuropathy populations and biological nerve measures | Further disease-specific signals | No broad treatment authorisation or general recovery evidence |
Outcome reading
A nerve-fibre measure and symptom benefit answer different questions
Corneal nerve-fibre density can provide an objective biological measure in small-fibre neuropathy research. A change may support a disease-modifying hypothesis, but it does not by itself prove less pain, better function or durable quality of life.
Patient-reported symptom scores are clinically relevant, yet small exploratory trials can be sensitive to missing data, multiple comparisons and chance. Confidence rises when prespecified patient-important outcomes reproduce in larger independent trials.
Claim boundary
Why the result does not generalise to every inflammatory or pain claim
Population
Selected research participants are not a general healthy population or every person with neuropathy.
Outcome
Symptom scales, nerve density, pain intensity and physical function may move differently.
Product
A defined investigational preparation does not authenticate a separate vial or establish clinical equivalence.
Development and product
Clinical development history is not marketplace verification
FDA’s current 503A category document lists cibinetide among substances nominated without adequate support for compounding. That category concerns the adequacy of a nomination under US compounding policy; it should not be misreported as a clinical-trial verdict or as proof of a specific safety problem.
A consumer vial still needs suitable identity, quantitative, impurity, aggregation, sterility and endotoxin evidence. A trial publication cannot show that a later batch from an unrelated supplier matches the investigational material.
Independence also affects confidence. Several key papers came from a connected development programme, and company-affiliated authors appear on parts of the literature. That does not invalidate the results. It increases the value of prospective replication by separate teams, complete protocol reporting and confirmation on outcomes that matter to patients rather than only on surrogate nerve measures.
Clinical signalNarrow neuropathy programme
DevelopmentNo identified marketing authorisation
US compoundingNomination lacked adequate support
VialSeparate quality question
Decision boundary
What remains unknown
- Whether benefits reproduce in larger, independent trials with patient-important outcomes.
- How durable any symptom or nerve-fibre effect is after treatment ends.
- Which neuropathy populations, if any, gain a net clinical benefit.
- The frequency of uncommon and long-term harms in larger exposure populations.
- Whether ARA-290 has any meaningful effect on unrelated pain, recovery or inflammatory claims.
- Whether a particular vial contains stable cibinetide at the stated amount and meets microbiological controls.
Evidence ledger
Sources and limits
These sources define the conclusions on this page. A citation supports only the proposition stated beside it.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| PubMed: 2012 ARA-290 pilot trial | A randomised double-blind pilot in 22 sarcoidosis patients reported a neuropathy symptom signal. | The very small study does not establish general pain or inflammation treatment. | |
| PubMed: 2013 ARA-290 trial | A blinded placebo-controlled study reported symptom and corneal nerve-fibre findings in sarcoidosis-associated neuropathy. | It does not establish benefit in unrelated conditions or consumer products. | |
| ClinicalTrials.gov: ARA-290 and corneal nerve fibres | The registered programme focused on neuropathic symptoms and nerve measures in sarcoidosis. | A registry does not broaden the population or prove all claims. | |
| PubMed: ARA-290 emotional-processing study | A small healthy-volunteer study did not unequivocally support an antidepressant-like profile. | It does not establish clinical treatment for mood or pain. | |
| FDA: 503A bulk substances categories | Cibinetide is listed in category 3, nominations without adequate support. | The category is not a product test or a complete clinical benefit-risk decision. |
Continue the investigation
Read the connected evidence
- why indication-specific evidence does not generaliseSee how population, outcome and directness control evidence transfer.
- the gut and inflammation claims assessedPlace ARA-290 beside other claims without converting neuropathy trials into a gut verdict.
- known versus unknown risksSeparate small monitored safety datasets from a mature risk estimate.
- what tests can proveReview the product attributes clinical papers do not authenticate.
Quick answers
Frequently asked questions
Is ARA-290 the same as cibinetide?
Yes. Cibinetide is the development name used for ARA-290, an engineered peptide studied in several narrow clinical programmes.
Does ARA-290 treat neuropathy?
Small sarcoidosis-associated neuropathy trials reported promising signals, but the programme does not establish routine treatment or a broad indication.
Does a corneal nerve-fibre change prove less pain?
No. It is an objective biological measure, but symptom relief, function and durability need their own prespecified outcomes.
Is cibinetide authorised in the UK?
No UK marketing authorisation was identified. Check the current MHRA products database for the exact product.
Does the FDA category 3 listing mean ARA-290 is proven unsafe?
No. Category 3 means the compounding nomination lacked adequate support. It is not a finding that every exposure causes a defined harm.
What remains unknown?
Larger independent confirmation, durable benefit, uncommon harms, broader indications and the quality of individual products remain unresolved.
Evidence library
Claim-level evidence records
Open the individual records behind this profile. Each record links to the primary and official sources used for its verdict.
Profile-to-record links checked 10 August 2026. These evidence records received named scientific and clinical sign-off on 10 August 2026.
Editorial experience
From our work: how we checked this page
For topical-map item O-011, ARA-290 and cibinetide: neuropathy trials and claim limits was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 5 unique external sources and 8 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.